Vulvodynia is not classified as an autoimmune disease. It is formally categorized as a chronic pain syndrome, specifically a diagnosis of exclusion, meaning it’s identified when no other cause for vulvar pain can be found. However, the relationship between vulvodynia and the immune system is more nuanced than a simple “no.” Research shows that immune dysfunction, including autoimmune-like reactions, likely plays a contributing role in at least some cases.
Why It Gets Confused With Autoimmune Disease
The confusion is understandable. In some women, vulvodynia appears to involve an immune response that has gone off track. Recurrent vaginal yeast infections or frequent use of local medications can trigger what researchers describe as a “cross-reacting immunological response to self antigens,” essentially the immune system mistakenly attacking the body’s own tissue in the vulvar area. This process looks a lot like autoimmunity and can drive chronic inflammation. But this mechanism doesn’t appear to be universal across all vulvodynia cases, which is one reason the condition hasn’t earned an autoimmune classification.
A large Swedish study tracking women born between 1973 and 1996 found a clear pattern: women with vulvodynia were significantly more likely to also have immune-related conditions. Compared to controls, they had 1.8 times the odds of immune deficiencies, 1.4 times the odds of single-organ autoimmune disorders, and 1.6 times the odds of multi-organ autoimmune conditions. They were also 1.7 times more likely to have allergies or atopic conditions like eczema. The more immune-related diagnoses a woman had, the stronger the association with vulvodynia. Women with three or more immune conditions had nearly triple the odds.
This doesn’t prove vulvodynia is autoimmune, but it strongly suggests the immune system is involved in the bigger picture for many women who develop it.
What’s Actually Happening in the Tissue
Rather than a single disease mechanism, vulvodynia appears to involve several overlapping processes. One of the most studied is the role of mast cells, immune cells that sit close to sensory nerves in the vulvar tissue. In vulvodynia, these cells proliferate and release inflammatory substances that irritate and sensitize nearby nerve fibers. Researchers have proposed that an unknown trigger drives this mast cell activity, which then causes the nerves to multiply and become hypersensitive to touch.
A feedback loop makes this worse. Once nerve fibers become sensitized, they release chemical signals that attract and activate even more mast cells. This process, called neurogenic inflammation, means the nervous system and the immune system essentially keep amplifying each other’s signals. The result is pain from stimuli that wouldn’t normally hurt, like light touch or the pressure of sitting.
Multiple studies have confirmed that women with vulvodynia have significantly higher nerve fiber density in the affected tissue compared to women without the condition. This excess of nerve fibers concentrates at the border between the outer skin layer and the tissue beneath it. Animal research has replicated this finding: mice exposed to repeated vulvar yeast infections develop lasting pain sensitivity and nerve overgrowth that persists weeks after the infection clears, mirroring what many women describe as vulvodynia that started after recurrent infections.
It Behaves More Like a Nerve Pain Condition
The treatments that work best for vulvodynia are the same ones used for neuropathic (nerve-based) pain conditions, which further supports its classification as a pain syndrome rather than an autoimmune disease. First-line treatment typically involves medications originally developed for depression or seizures that also calm overactive nerve signals. These can be taken orally or applied as topical creams directly to the vulvar area.
Topical numbing agents are also commonly used. One study found that 76% of participants were able to have intercourse after treatment, compared to only 36% before. Results vary, though, and finding the right approach often involves trial and error.
The neuropathic framing matters because it shapes treatment expectations. Autoimmune diseases are typically managed by suppressing the immune system. Vulvodynia is managed by calming the nervous system, reducing local inflammation, and addressing the physical tension that often accompanies it.
The Pelvic Floor Connection
Nearly all women with vulvodynia also have overactive pelvic floor muscles. One study using a validated assessment protocol found that 98.7% of participants met the criteria for pelvic floor muscle overactivity. This isn’t a coincidence. When the vulvar area is in chronic pain, the surrounding muscles tighten protectively and often can’t fully relax. This muscle tension can itself become a source of pain, creating yet another self-reinforcing cycle.
Pelvic floor physical therapy is a standard part of vulvodynia management for this reason. A specialized therapist works on releasing the chronically contracted muscles, which can meaningfully reduce pain even though it doesn’t address the underlying nerve or immune changes directly.
A Condition With Multiple Drivers
The most accurate way to think about vulvodynia is as a chronic pain condition with immune, neurological, muscular, and possibly genetic components. Some women may have a version that is more immune-driven, particularly those with histories of recurrent infections or other autoimmune conditions. Others may have a version more rooted in nerve changes or pelvic floor dysfunction. In most cases, several of these factors overlap.
The immune system’s role is real and supported by solid evidence, but vulvodynia doesn’t fit the classic autoimmune pattern of a clearly identified antibody attacking a specific tissue. It sits in a gray zone: not autoimmune by formal definition, but not entirely separate from the immune system either. For women who have vulvodynia alongside other immune conditions, this connection is worth discussing with a provider, since it may influence which treatments are most effective.